Medicenna Therapeutics Selects Kalon Biotherapeutics To Manufacture New Cancer Drug
PTSM: Pharmaceutical Technology Sourcing and Management
Medicenna Therapeutics selects Kalon Biotherapeutics to manufacture a new brain cancer drug for children and adults.
Medicenna Therapeutics, a clinical stage immune-oncology company, has selected Kalon Biotherapeutics, an advanced biologics contract development and manufacturing company, to manufacture materials that will accelerate the development, testing, and Phase 3/commercialization of several new cancer drugs in the pipeline. The operations of Kalon Biotherapeutics are located in the National Center for Therapeutics Manufacturing on the campus of Texas A&M in College Station, Texas.
Kalon’s first project with Medicenna is for a clinical trial testing the effectiveness of Medicenna’s empowered cytokines (ECs) for children with brain cancer. The agreement provides for Kalon to manufacture the material that will be used in human clinical trials in children and adults with brain cancer.
Source: Kalon Biotherapeutics
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
